SEC Form 4 · accession 0001209191-15-028979
ImmunoCellular Therapeutics, Ltd. · IMUC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John S Yu
Officer — See Remarks · Director
Period of report
Mar 20, 2015
Accepted (ET)
Mar 24, 2015 · 6:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000822411
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Rt to Buy)F1 | $0.57 | Mar 20, 2015 | A | 100,000 | A | — | Mar 20, 2020 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1Option shares shall vest in a series of 48 equal consecutive monthly installments commencing on April 13, 2015 until fully vested.
Remarks
Chief Scientific Officer and Chairman